Published • loading... • Updated
'I thought I was going to die': stroke drug breakthrough for patients
Early phase-two results suggest the anti-clotting drug could reduce long-term disability and speed access to stroke treatment across Australia.
- On Wednesday, NSW Premier Chris Minns attended an announcement at John Hunter Hospital highlighting positive results from a clinical trial of the anti-clotting drug TBO-309 designed to improve stroke recovery.
- About 46,000 Australians experience strokes annually, often facing long-term disability. Thrombio's TBO-309 targets disease-causing clots to restore blood flow while avoiding bleeding complications, offering a safer alternative to standard therapies.
- Toronto resident Alan Johnson, 76, suffered a severe stroke on February 13, leaving him unable to speak or move. Following treatment with TBO-309, he regained movement by the fourth day, stating, "By the afternoon, I could lift my leg as high as I normally would."
- Professor Shaun Jackson, founder of Thrombio, said early results offer the "possibility of not just saving lives after stroke, but meaningfully improving how people recover." Jackson added this could change stroke treatment globally if results continue.
- Health Minister Ryan Park stated, "These early results are very promising," as researchers plan to expand the clinical trial into additional hospitals across Australia and equip paramedics with TBO-309 for faster emergency intervention.
Insights by Ground AI
32 Articles
32 Articles
+31 Reposted by 31 other sources
'I thought I was going to die': stroke drug breakthrough for patients
Stroke breakthrough with Thrombio drug TBO-309. Alan Johnson shares how the drug helped him. Chris Minns and Ryan Park to attend trial results at John Hunter
·Newcastle, Australia
Read Full ArticleCoverage Details
Total News Sources32
Leaning Left23Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium



